Latest Headlines
-
Altesa BioSciences Recognizes Co-Founder And Partner For Major NIH Research Grant To Discover New Antiviral Drugs
5/25/2022
Altesa BioSciences, Inc., a clinical-stage biopharmaceutical company developing and commercializing novel antiviral drugs against common respiratory viruses and global viral threats, today recognized George Painter, PhD, a co-founder of Altesa and chairman of the Altesa Scientific Advisory Board for earning a major research grant from the National Institute of Allergy and Infections Diseases (NIAID), part of the National Institutes of Health
-
Excelra Partners With Hotspot Therapeutics To Enhance Allosteric Drug Discovery Efforts
5/25/2022
Excelra, a leading global data and digital insights organization, today announced a partnership with HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule allosteric therapies for the treatment of cancer and autoimmune diseases.
-
Galapagos In-Licenses Novel Drug Targets For Inflammatory Bowel Disease Discovered By Scipher Medicine’s Spectra Platform
5/24/2022
Scipher Medicine today announced that Galapagos has exercised its option to in-license novel drug targets for inflammatory bowel disease (IBD) discovered by Scipher’s Spectra™ platform.
-
Noveome Biotherapeutics, Inc. Receives Rare Pediatric Disease Designation And Orphan Drug Designation For The Treatment Of Necrotizing Enterocolitis In Neonates
5/24/2022
Noveome Biotherapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to the company’s lead product ST266 for the treatment of Necrotizing Enterocolitis (NEC)
-
Ceruvia Lifesciences Submits FDA Investigational New Drug Application For Psilocybin Obsessive-Compulsive Disorder Program
5/24/2022
Ceruvia Lifesciences, a leading neurotransformational medicine biopharmaceutical company today announced the submission of an IND application to begin a Phase 2, multicenter, randomized, double blind, active placebo controlled clinical trial to to determine the efficacy and safety of a single oral dose of synthetic psilocybin (SYNP-101) in treating obsessive-compulsive disorder (OCD) symptoms up to 12 weeks after dosing
-
Research Boosts 'Game-Changing' Technology To Strengthen Drug Development
5/24/2022
Researchers have boosted pioneering technology to show whether potential treatments are worth progressing into human trials, in a game-changing move that could dramatically reduce the high failure rates in drug discovery and development
-
U Of M Receives NIAID Grant To Develop Drug Treatments For Future Viral Pandemics
5/23/2022
The University of Minnesota has received $66M from the National Institute of Allergy and Infectious Diseases (NIAID) to establish a center to develop antiviral drugs for pandemic-level viruses, including SARS-CoV-2
-
TherapeuticsMD Receives U.S. Food And Drug Administration (FDA) Approval For Supplemental New Drug Application (sNDA) For ANNOVERA
5/20/2022
TherapeuticsMD, Inc. (“TXMD” or the “Company”), an innovative, leading women’s healthcare company, today announced the FDA’s approval of a supplemental New Drug Application (sNDA) for ANNOVERA
-
Almac Discovery And Hitgen Announce Strategic Research Collaboration
5/20/2022
Almac Discovery, the research driven drug discovery company and a member of the Almac Group, today announced a new research collaboration with HitGen Inc., a world leader in the development and application of DNA-encoded library (DEL) technology for novel chemical equity (NCE) generation.
-
New Study Shows Genes Can Predict Response To Arthritis Treatment And Paves The Way For Future Drug Development
5/19/2022
New research from Queen Mary University of London, published in Nature Medicine, has shown that molecular profiling of the diseased joint tissue can significantly impact whether specific drug treatments will work to treat rheumatoid arthritis (RA) patients.